Summary | |
---|---|
Symbol | RUNX2 |
Name | runt-related transcription factor 2 |
Aliases | AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ...... |
Chromosomal Location | 6p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus |
Domain |
PF00853 Runt domain PF08504 Runx inhibition domain |
Function |
Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis (PubMed:28505335, PubMed:28738062, PubMed:28703881). Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Inhibits KAT6B-dependent transcriptional activation. |
Biological Process |
GO:0001501 skeletal system development GO:0001503 ossification GO:0001649 osteoblast differentiation GO:0001958 endochondral ossification GO:0002051 osteoblast fate commitment GO:0002062 chondrocyte differentiation GO:0002063 chondrocyte development GO:0002076 osteoblast development GO:0002521 leukocyte differentiation GO:0007159 leukocyte cell-cell adhesion GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway GO:0007224 smoothened signaling pathway GO:0008543 fibroblast growth factor receptor signaling pathway GO:0008589 regulation of smoothened signaling pathway GO:0021700 developmental maturation GO:0030098 lymphocyte differentiation GO:0030217 T cell differentiation GO:0030278 regulation of ossification GO:0030326 embryonic limb morphogenesis GO:0030509 BMP signaling pathway GO:0032330 regulation of chondrocyte differentiation GO:0032332 positive regulation of chondrocyte differentiation GO:0035107 appendage morphogenesis GO:0035108 limb morphogenesis GO:0035113 embryonic appendage morphogenesis GO:0035115 embryonic forelimb morphogenesis GO:0035136 forelimb morphogenesis GO:0036075 replacement ossification GO:0040036 regulation of fibroblast growth factor receptor signaling pathway GO:0042110 T cell activation GO:0042475 odontogenesis of dentin-containing tooth GO:0042476 odontogenesis GO:0042481 regulation of odontogenesis GO:0042487 regulation of odontogenesis of dentin-containing tooth GO:0044344 cellular response to fibroblast growth factor stimulus GO:0045165 cell fate commitment GO:0045667 regulation of osteoblast differentiation GO:0045669 positive regulation of osteoblast differentiation GO:0045778 positive regulation of ossification GO:0045879 negative regulation of smoothened signaling pathway GO:0048469 cell maturation GO:0048562 embryonic organ morphogenesis GO:0048568 embryonic organ development GO:0048701 embryonic cranial skeleton morphogenesis GO:0048704 embryonic skeletal system morphogenesis GO:0048705 skeletal system morphogenesis GO:0048706 embryonic skeletal system development GO:0048736 appendage development GO:0048863 stem cell differentiation GO:0051216 cartilage development GO:0060173 limb development GO:0060348 bone development GO:0060349 bone morphogenesis GO:0060350 endochondral bone morphogenesis GO:0061035 regulation of cartilage development GO:0061036 positive regulation of cartilage development GO:0061448 connective tissue development GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0071593 lymphocyte aggregation GO:0071772 response to BMP GO:0071773 cellular response to BMP stimulus GO:0071774 response to fibroblast growth factor GO:0090287 regulation of cellular response to growth factor stimulus GO:1901522 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1904888 cranial skeletal system development GO:2000027 regulation of organ morphogenesis |
Molecular Function |
GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001046 core promoter sequence-specific DNA binding GO:0001047 core promoter binding GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001159 core promoter proximal region DNA binding GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0003682 chromatin binding GO:0008134 transcription factor binding GO:0043425 bHLH transcription factor binding GO:0070491 repressing transcription factor binding |
Cellular Component |
GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0005667 transcription factor complex GO:0044454 nuclear chromosome part |
KEGG | - |
Reactome |
R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-2032785: YAP1- and WWTR1 (TAZ)-stimulated gene expression |
Summary | |
---|---|
Symbol | RUNX2 |
Name | runt-related transcription factor 2 |
Aliases | AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ...... |
Chromosomal Location | 6p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between RUNX2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | RUNX2 |
Name | runt-related transcription factor 2 |
Aliases | AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ...... |
Chromosomal Location | 6p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of RUNX2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | RUNX2 |
Name | runt-related transcription factor 2 |
Aliases | AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ...... |
Chromosomal Location | 6p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of RUNX2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of RUNX2 in various data sets.
|
Summary | |
---|---|
Symbol | RUNX2 |
Name | runt-related transcription factor 2 |
Aliases | AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ...... |
Chromosomal Location | 6p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RUNX2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | RUNX2 |
Name | runt-related transcription factor 2 |
Aliases | AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ...... |
Chromosomal Location | 6p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RUNX2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RUNX2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | RUNX2 |
Name | runt-related transcription factor 2 |
Aliases | AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ...... |
Chromosomal Location | 6p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RUNX2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | RUNX2 |
Name | runt-related transcription factor 2 |
Aliases | AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ...... |
Chromosomal Location | 6p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of RUNX2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | RUNX2 |
Name | runt-related transcription factor 2 |
Aliases | AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ...... |
Chromosomal Location | 6p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between RUNX2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | RUNX2 |
Name | runt-related transcription factor 2 |
Aliases | AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ...... |
Chromosomal Location | 6p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting RUNX2 collected from DrugBank database. |
There is no record. |